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Abstract: Retinoids are required for maintaining many essential physiological processes in 
the body, including normal growth and development, normal vision, a healthy immune 
system,  normal  reproduction,  and  healthy  skin  and  barrier  functions.  In  excess  of 
500 genes are thought to be regulated by retinoic acid. 11-cis-retinal serves as the visual 
chromophore in vision. The body must acquire retinoid from the diet in order to maintain 
these  essential  physiological  processes.  Retinoid  metabolism  is  complex  and  involves 
many different retinoid forms, including retinyl esters, retinol, retinal, retinoic acid and 
oxidized and conjugated metabolites of both retinol and retinoic acid. In addition, retinoid 
metabolism  involves  many  carrier  proteins  and  enzymes  that  are  specific  to  retinoid 
metabolism, as well as other proteins which may be involved in mediating also triglyceride 
and/or  cholesterol  metabolism.  This  review  will  focus  on  recent  advances  for 
understanding retinoid metabolism that have taken place in the last ten to fifteen years.  
Keywords:  chylomicron;  carotenoid;  retinol-binding  protein  (RBP);  lecithin:retinol 
acyltransferase (LRAT); hepatocyte; hepatic stellate cell; adipocyte 
Abbreviations: ABCA1: ATP-binding cassette, sub-family A, member 1; ABCR: ATP 
binding cassette transporter; APO: apolipoprotein; ARAT: acyl-CoA:retinol acyltransferase; 
ATGL:  adipose  triglyceride  lipase;  BCMO1:  β-carotene-15,15′-monooxygenase;  
BCMO2: β-carotene-9′,10′-monooxygenase; CEL: carboxyl ester lipase; CRABP: cellular 
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retinoic acid-binding protein; CRBPI, -II, and -III: cellular retinol-binding protein, type I,  
-type  II  and  -type  III;  DGAT1:  diacylglycerol  acyltransferase  1;  GI:  gastrointestinal; 
GLUT4:  glucose  transporter  4;  HDL:  high  density  lipoprotein;  HPSG:  heparin  sulfate 
proteoglycans; HSC: hepatic stellate cell; HSL: hormone sensitive lipase; ISX: intestine 
specific  homeobox;  LDL:  low  density  lipoprotein;  LPL:  lipoprotein  lipase;  
LRAT: lecithin:retinol acyltransferase; LRP: LDL receptor-related protein; MEF: myocyte 
enhancer  factor;  NAFLD:  non-alcoholic  fatty  liver  disease;  PLRP1:  pancreatic  lipase 
related  protein  1;  PLRP2:  pancreatic  lipase  related  protein  2;  PPAR:  peroxisome 
proliferator-activated receptor; PPRE: peroxisome proliferator-activated receptor response 
elements; PTL: pancreatic triglyceride lipase; RBP: retinol-binding protein; RDH: retinol 
dehydrogenase;  REH:  retinyl  ester  hydrolase;  RPE:  retinal  pigment  epithelium  protein; 
siRNA: small inhibitory RNA; SNP: single nucleotide polymorphism; SR-B1: scavenger 
receptor  class  B,  type  I;  STRA6:  stimulated  by  retinoic  acid  6;  TTR:  transthyretin;  
VLDL: very low density lipoprotein; WT: wild type. 
 
1. Introduction 
It is nearly 100 years since the identification of vitamin A [1] in 1913 by McCollum and Davis [2], 
but much still remains to be learned about natural retinoid (vitamin A) metabolism and actions in the 
body. Many major questions regarding how retinoids are taken up from the diet and the molecular 
events  important  to  retinoid  storage  and  metabolism  within  specific  cells  and  tissues  need  to  be 
answered. Nevertheless, in the near 100 years that have gone by since the work of McCollum and 
Davis, a very extensive literature focused on retinoid metabolism and actions has accumulated. Our 
goal is to review important advances that have been  made during the last 10 to 15 years toward 
understanding retinoid metabolism. This review will not concentrate on earlier work, as we will only 
briefly discuss what is known regarding retinoid metabolism from earlier published work to facilitate 
understanding of recent advances. For more information regarding seminal older research, the reader is 
referred to a number of extensive reviews published in the 1980s and 1990s to which this will serve as 
an update [3–6].  
This review will focus primarily on (i) the intestinal absorption and metabolism of retinoid within 
the enterocyte; (ii) retinoid uptake, processing, and storage within the liver, where 70% of the retinoid 
stored within the body is located; and (iii) retinoid storage and metabolism in a number of extrahepatic 
tissues that have been the focus of recent research interest or where retinoid uptake and metabolism 
may be an integral component of the physiology of the tissue. The review will be primarily focused on 
mammals, with a few pertinent references to zebrafish, chickens and other non-mammalian species. 
We will not consider the molecular actions of retinoids in regulating retinoid-responsive transcription 
or their non-transcriptional actions. We will also not consider the metabolism of retinol to retinal or 
retinoic acid. Similarly, the potential roles of retinoids in either the prevention or causation of disease 
will be briefly discussed but not extensively covered.  Nutrients 2011, 3  
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2. Metabolism within the Gastrointestinal (GI) Tract 
Retinoid metabolism within the GI tract occurs predominantly within the proximal portion of the 
small intestine and involves metabolic events that occur both in the lumen, as well as within the 
enterocyte [3–6]. These events are summarized in  Figure 1 and are discussed below. For optimal 
retinoid absorption, fat must be consumed along with the newly ingested retinoid. This fat is needed to 
facilitate retinoid entry into enterocytes from the lumen of the gut. In addition, a fat load is needed to 
allow for optimal chylomicron formation, since retinoids, like other dietary lipids, enter the body as a 
component of nascent triglyceride-rich chylomicrons.  
Figure  1.  General  scheme  for  the  uptake  and  metabolism  of  dietary  retinoids  and 
proretinoid  carotenoids  within  the  intestine.  Dietary  proretinoid  carotenoids,  like  
β-carotene, are taken up into the enterocyte through a process that involves SR-B1. Once 
inside  the  enterocyte,  β-carotene  can  be  acted  upon  by  BCMO1  and  either  converted  
to  retinal,  which  binds  CRBPII,  or  can  be  incorporated  intact  and  unmodified  along  
with  dietary  fat  and  cholesterol  into  nascent  chylomicrons.  The  retinal  produced  from  
β-carotene cleavage must undergo reduction to retinol. This is catalyzed by one or more 
not well-characterized retinal reductases. Upon conversion to retinol, the retinol formed 
from  dietary  proretinoid  carotenoids  is  metabolically  indistinguishable  from  retinoid 
arriving in the diet as preformed retinoid. Dietary retinyl ester is either hydrolyzed in the 
lumen of the intestine by PTL or PLRP2 or undergoes hydrolysis at the intestinal brush 
border catalyzed by a brush border REH. Retinol taken into the enterocyte binds to CRBPII 
and is esterified to retinyl ester. In response to a physiological challenge of retinol, LRAT 
will  catalyze  approximately  90%  of  retinyl  ester  formation,  while  the  intestinal 
acyl-CoA:retinol  acyltransferase,  DGAT1,  catalyzes  the  remainder  of  retinyl  ester 
formation. The resulting retinyl ester is then packed along with dietary fat and cholesterol 
into nascent chylomicrons, which are secreted into the lymphatic system.  
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The  intestine  is  the  primary  tissue  within  the  body  where  dietary  proretinoid  carotenoids,  like  
β-carotene,  are  converted  to  retinoid.  Dietary  proretinoid  carotenoids,  as  well  as  non-proretinoid 
carotenoids like lycopene and lutein, are incorporated into nascent chylomicrons and thus enter into the 
general circulation and the body. 
2.1. Dietary Forms and Metabolism in the Lumen of the Intestine  
Retinoid arrives from the diet either as preformed retinoid, consisting predominantly of retinol and 
retinyl ester, or as proretinoid carotenoids, which can be converted to retinoid within the intestine and 
other tissues. Human serum contains -carotene, -carotene, cryptoxanthin, lycopene, and lutein as 
major components, with smaller concentrations of zeaxanthin, other xanthophylls, and polyenes such 
as phytofluene and phytoene, which are all acquired from the diet [7]. 
The key digestive processes that occur within the lumen of the intestine include the physical release 
of dietary retinoids and proretinoid carotenoids from the food matrix and their emulsification with 
dietary fatty acids and bile acids. Emulsification with free fatty acids and bile salts is required to 
facilitate uptake of the highly insoluble retinoids and carotenoids into enterocytes from the lumen [3–6]. 
Dietary retinol is taken up directly from the lumen into the enterocyte; however, dietary retinyl 
esters must first undergo enzymatic hydrolysis within the lumen or at the enterocyte brush border to 
allow for uptake of the hydrolysis product retinol [3–6]. The identities of pancreatic enzymes that act 
in a physiologically significant manner in retinyl ester hydrolysis within the lumen were explored 
systematically in the last decade using both induced mutant mice and biochemical approaches [8,9]. 
Weng et al. reported studies of dietary cholesteryl ester and dietary retinyl ester absorption in wild  
type (WT) and carboxyl ester lipase (CEL) knockout mice [8]. These authors showed that, compared to 
WT mice, mice totally deficient in CEL absorbed only about 50% of the cholesterol provided as 
cholesteryl ester. Although earlier published work had proposed that CEL acted importantly within the 
lumen to catalyze retinyl ester hydrolysis, WT and CEL-deficient mice absorbed similar amounts of 
retinol  when  it  was  provided  in  a  gavage  as  retinyl  ester.  Based  on  these  findings,  Weng  et  al. 
concluded that enzymes other than CEL must participate in the hydrolysis of dietary cholesteryl esters 
and retinyl esters within the GI tract [8]. This group of investigators subsequently reported studies that 
involved  the  separation  and  partial  purification  of  pancreatic  CEL  and  pancreatic  triglyceride  
lipase  (PTL)  by  DEAE-chromatography  [9].  For  both  rats  and  mice,  pancreatic  retinyl  ester  
hydrolase  (REH)  activity,  measured  by  in  vitro  assay,  was  attributed  mainly  to  PTL  and,  to  a 
quantitatively lesser extent, to CEL. Purified human PTL was reported to exhibit similar enzymatic 
characteristics for both triglyceride hydrolysis and retinyl ester hydrolysis. Based on these biochemical 
data,  it  was  concluded  that  PTL  is  the  major  pancreatic  REH  activity  in  rats  and  mice  and  is  a 
catalytically active REH in humans, as well [9].  
Purified horse PTL was reported by Reboul et al. to hydrolyze retinyl ester when provided either in 
triglyceride-rich  lipid  droplets,  mixed  micelles  or  vesicles  [10].  It  was  further  reported  by  these 
investigators  that  purified  dog  pancreatic  lipase-related  protein  2  (PLRP2),  but  not  purified  horse 
pancreatic lipase related protein 1 (PLRP1), catalyzes retinyl ester hydrolysis [10]. PLRP2-catalyzed 
retinyl ester hydrolysis required the presence of pancreatic colipase in order for activity to be observed. 
PLRP2 showed activity towards retinyl ester that had been incorporated into mixed micelles, but not Nutrients 2011, 3  
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emulsions. Based on these data, it was proposed that PTL and PLRP2 act synergistically within the 
lumen  to  catalyze  dietary  retinyl  ester  hydrolysis,  enhancing  the  overall  efficiency  of  retinoid 
absorption [10]. 
2.2. Metabolism and Processing within the Intestinal Mucosa  
The  intestine  is  the  primary  site  of  proretinoid  carotenoid  metabolism  in  the  body.  Dietary 
proretinoid carotenoids are taken up intact into the enterocyte, where they can undergo conversion to 
retinoid or be packaged unmodified into chylomicrons. During the past decade, considerable research 
activity has been focused on carotenoid uptake into, and conversion to retinoid, within the intestine. 
Similarly,  there  has  been  considerable  progress  made  towards  a  better  understanding  of  retinoid 
metabolism within the enterocyte. 
2.2.1. Uptake into and Efflux from the Enterocyte  
Both  in  vivo  studies,  involving  the  use  of  mutant  mouse  models,  and  in  vitro  cell  culture 
experiments have established scavenger receptor class B, type I (SR-B1) as a key a mediator for uptake 
of β-carotene from the intestinal lumen into the enterocyte [11–13]. Van Bennekum et al. studied 
cholesterol and β-carotene uptake by WT and SR-B1 knockout mice and concluded that SR-B1 is 
required for β-carotene absorption, at least for mice consuming a high fat diet [11]. These authors 
further showed that both SR-B1 and the plasma membrane fatty acid transporter CD36 can facilitate 
absorption of dietary cholesterol, but van Bennekum et al. were unable to establish whether SR-B1 
acts essentially in vivo in facilitating this cholesterol uptake [11]. No evidence was obtained that CD36 
acts in facilitating β-carotene absorption. SR-B1 expression in transfected COS-7 cells [11] and in 
intestinal Caco-2 cells [12] was found to confer on these cells the ability to take up β-carotene from 
mixed bile salt micelles, phospholipid small unilamellar vesicles, and triglyceride emulsions, thus, 
providing further evidence for a role for SR-B1 in β-carotene absorption. In addition to facilitating 
mucosal uptake of the proretinoid carotenoid β-carotene, SR-B1 also acts in facilitating uptake into the 
enterocyte of the non-proretinoid carotenoids lycopene and lutein [14,15]. 
Retinol  uptake  into  cultured  intestinal  Caco-2  cells  has  been  reported  by  During  and  Harrison  
to occur via both a saturable process, when retinol was provided at concentrations below 10 µ M,  
and a nonsaturable process at higher retinol concentrations [12]. Expression of SR-B1 is not required  
for  retinol  uptake  into  Caco-2  cells,  since  knockdown  of  SR-B1  expression  with  small  
inhibitory  RNAs  (siRNAs)  failed  to  influence  retinol  uptake  by  the  cells  [12].  Interestingly,  
inhibition  of  expression  of  the  cholesterol  efflux  transporter  ATP-binding  cassette,  sub-family  A, 
member 1 (ABCA1) in Caco-2 cells through use of either siRNAs or the drug glyburide, which inhibits 
transport  activity  of  ATP-binding  cassette  family  members  including  ABCA1,  diminished  retinol 
efflux from the basolateral surface of the polarized cultures of Caco-2 cells [12]. These findings led to 
the proposal that retinol efflux from enterocytes is probably partially facilitated by the basolateral 
cholesterol transporter ABCA1. However, later studies by Reboul et al., making use of both Caco-2 
cells and ABCA1-deficient mice, failed to confirm this earlier observation [16]. Although Reboul et al. 
were able to convincingly demonstrate a role for ABCA1 in facilitating absorption of both α- and  Nutrients 2011, 3  
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γ-tocopherol, their data provide no support for the idea that ABCA1 contributes to retinoid efflux, in 
nascent chylomicrons, from enterocytes [16].  
2.2.2. Enzymatic Conversion of Proretinoid Carotenoid to Retinoid  
The  enzymes  involved  in  converting  proretinoid  carotenoids  to  retinoid  were  long  a  matter  of 
heated research controversy [5,6]. From studies undertaken in the late 1950s and early 1960s, it was 
clear  that  enzymes  existed  within  mammalian  tissues  that  are  able  to  cleave  β-carotene,  either 
symmetrically  at  its  central  15,15′  carbon-carbon  double  bond,  forming  two  molecules  of 
retinaldehyde,  or  asymmetrically  at  other  carbon-carbon  double  bonds,  forming  two  products  of 
unequal chain length (see Figure 2 below). Largely owing to technical difficulties in purifying and 
cloning these enzymes, from the 1970s through the 1990s, there was considerable debate as to whether 
only the central cleavage reaction contributed to retinoid formation or whether asymmetric cleavage 
also gave rise to quantitatively significant retinoid formation. This controversy was resolved in the last 
decade with the cloning and study of cDNA for two gene products, Bcmo1 and Bcmo2, which encode 
enzymes able to catalyze central and asymmetric β-carotene cleavage, respectively. cDNAs for Bcmo1 
have now been cloned for the chicken [17], mouse [18–20], rat [21], and human [22,23], as well as for 
the fruit fly [24] and zebrafish [25]. Kiefer et al. reported cloning cDNAs for Bcmo2 from the fruit fly, 
zebrafish, and the mouse and human [26]; whereas, Hu et al. reported cloning the ferret cDNA [27].  
It is now established that only the Bcmo1 gene product, which encodes an enzyme able to catalyze the 
central cleavage of β-carotene, is significant within the body for mediating retinoid formation from 
dietary proretinoid carotenoids [28,29]. 
Figure  2.  Carotenoids  can  undergo  cleavage  either  symmetrically  by  BCMO1  or 
asymmetrically by BCMO2. 
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Two  st ructurally  related  proteins,  β-carotene-15,15′-monooxygenase  (BCMO1),  encoded  by 
Bcmo1, and β-carotene-9′,10′-monooxygenase (BCMO2), encoded by Bcmo2, are the sole mammalian 
enzymes known to cleave carotenoids. BCMO1 and BCMO2 are highly homologous to each other, 
with mouse BCMO1 and BCMO2 sharing 39% sequence identity. Each has a high degree of sequence 
homology  to  the  retinal  protein  RPE65,  which  catalyzes  the  isomerization  of  all-trans-retinoid  Nutrients 2011, 3  
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to  the  11-cis-isomer  for  use  in  the  visual  cycle  (see  Section  5.3  below  for  more  details).  The  
older  literature,  based  on  the  study  of  only  partially  purified  enzyme,  referred  to  BCMO1  as  
β-carotene-15,15′-dioxygenase, rather than as a monooxygenase [3–6]. However, a reevaluation of the 
reaction mechanism for this enzyme, employing recombinant protein, indicated that it acts through  
a monooxygenase, rather than a dioxygenase mechanism [30]. Biochemical data obtained by different 
laboratories  regarding  the  properties  and  expression  of  mammalian  BCMO1  are  in  general  
agreement [17–23]. BCMO1 is a soluble, Fe
2+-containing, 63 kDa protein. It is expressed in the small 
intestine (at higher levels more proximal to the stomach), liver, kidney, lungs, skin, testis, the retinal 
pigment epithelium within the eye, and in a number of embryonic tissues.  
The biochemical properties and expression of BCMO2 have been less extensively studied than 
those of BCMO1. Like BCMO1, BCMO2 contains Fe
2+ and has a cytoplasmic localization within  
the cell [26,27]. Both recombinant mouse and ferret BCMO2 catalyze cleavage of β-carotene at its 
9′,10′ carbon-carbon double bond, and both will catalyze lycopene cleavage at its 9′,10′ carbon-carbon 
double bond [26,27]. In the mouse, Bcmo2 is expressed in small intestine, liver, kidney, spleen, brain, 
and heart [26]. A similar tissue distribution has been reported for the ferret [27]. 
2.2.3. The Bcmo1 and Bcmo2 Genes and Their Expression  
The  gene  for  Bcmo1  and  the  regulation  of  its  expression  have  been  studied  by  a  number  of 
laboratories. The mouse and human genes for Bcmo1 have both been shown to contain functional 
peroxisome  proliferator-activated  receptor  (PPAR)  response  elements  (PPREs)  [31,32].  The  PPRE 
present in the mouse gene is located within 60 bp upstream of the start site, and deletion or mutation of 
this element reduces promoter activity to its basal level [31]. Electrophoretic mobility shift assays 
established  that  PPARγ  specifically  binds  this  site,  and  administration  of  the  PPARα/γ  agonist 
WY14643  stimulated  promoter  activity  in  reporter  assays,  as  well  as  increased  BCMO1  protein 
expression  in  livers  of  mice  administered  the  agonist.  Using  similar  experimental  approaches,  
Gong  et  al.  established  that  the  human  Bcmo1  gene  contains  a  functional  PPRE  in  its  proximal 
promoter [32]. Moreover, these investigators demonstrated that the proximal promoter of the human 
Bcmo1  gene  also  contains  a  functional  myocyte  enhancer  factor  2  (MEF2)  binding  element  and 
reported  data  suggesting  that  MEF2C,  one  member  of  the  MEF2  transcription  factor  family,  and 
PPARγ interact synergistically to transactivate Bcmo1 expression.  
Other transcription factors may also play important roles in regulating Bcmo1 expression, especially 
in intestine. Takitani et al. reported that intestinal Bcmo1 mRNA expression was markedly increased in 
rats fed a retinoid-deficient diet and that expression was suppressed upon feeding of either all-trans- or 
9-cis-retinoic acid [21]. However, although Takitani et al. demonstrated actions of retinoic acid in 
modulating intestinal Bcmo1 expression, they couldn’t explain the molecular basis for their observation. 
Further insight was provided by subsequent work from Seino et al. [33] and Lobo et al. [13]. Seino et al. 
reported that the intestine-specific transcription factor Isx (intestine specific homeobox) plays a key 
role in regulating expression of Bcmo1 in the mouse intestine [33]. These investigators, who generated 
and studied Isx-deficient mice through knock-in of LacZ, convincingly established that mRNA levels 
for both Bcmo1 and SR-B1 are greatly increased in the intestines of Isx-knockout mice. They further 
showed  that  severe  vitamin  A-deficiency  markedly  decreased  Isx  expression  and  that  this  was Nutrients 2011, 3  
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accompanied by an increase in Bcmo1 expression in both duodenum and jejunum. Based on their data, 
Seino et al. suggested that Isx participates in the maintenance of retinoid metabolism by regulating 
Bcmo1 expression in intestine. Lobo et al. carried this idea further by showing that retinoic acid, acting 
through  retinoic  acid  receptors,  induces  Isx  expression  [13].  This  effect  of  retinoic  acid  on  Isx 
expression  resulted  in  repression  of  both  the  Bcmo1  and  SR-B1  genes.  Through  study  of  
BCMO1-deficient mice, Lobo et al. were also able to establish that increased SR-B1 expression and 
systemic β-carotene accumulation could be prevented through administration of dietary retinoid, which 
induced Isx expression, resulting in a downregulation of SR-B1 expression and β-carotene uptake and 
systemic accumulation. Thus, the work of Lobo et al. established the existence of a diet-responsive 
regulatory  network  that  controls  β-carotene  absorption  and  retinoid  production  through  negative 
feedback regulation of Isx [13]. 
A  number  of  single  nucleotide  polymorphisms  (SNPs)  in  the  human  Bcmo1  gene  have  been 
identified. One of these, a T170M missense mutation, results in a 90% reduction in enzyme activity 
when  analyzed  in  vitro  using  purified  recombinant  enzymes  [34].  A  person  identified  as  being 
heterozygous for the T170M mutation was reported in an earlier study to possess very high levels of 
serum β-carotene (14.8 µ M), even though consuming only a typical Western diet not supplemented 
with β-carotene. Two common SNPs in the Bcmo1 gene, R267S and A379V, alter β-carotene uptake in 
female volunteers receiving a pharmacologic dose (120 mg) of β-carotene [35]. Both variant alleles, 
when studied as recombinant proteins, showed reduced catalytic activity towards β-carotene. Carriers 
of both the 379V and 267S + 379V variant alleles displayed reduced ability to convert β-carotene, as 
indicated  through  reduced  retinyl  palmitate:β-carotene  ratios  in  the  triglyceride-rich  lipoprotein 
fraction and increased fasting plasma β-carotene concentrations. Collectively, these data from SNP 
studies provide a compelling molecular explanation for why some individuals may be better able than 
others to take up and/or convert proretinoid carotenoids to retinoids.  
The structure and regulation of the Bcmo2 gene have been much less extensively studied than is the 
case for Bcmo1. Mutations in the Bcmo2 gene have been identified, and these influence carotenoid 
accumulation in chickens [36], cows [37] and sheep [38]. In domestic chickens, yellow skin coloration 
was found to be caused by a regulatory mutation that prevents expression of the Bcmo2 gene in skin, 
allowing for accumulation of yellow carotenoids [36]. In cows, a mutation giving rise to a premature 
stop codon in the Bcmo2 gene results in increased β-carotene concentrations in both serum and milk [37]. 
In sheep, a nonsense mutation in the Bcmo2 gene is strongly associated with high levels of carotenoids 
deposited in fat, resulting in a yellow fat phenotype [38]. 
2.2.4. Enterocyte Esterification of Retinol  
Newly absorbed dietary retinol within the enterocyte must be esterified prior to its packaging as 
retinyl ester in nascent chylomicrons. The older literature had indicated that the intestine possesses two 
distinct  enzyme  activities  able  to  synthesize  retinyl  esters  from  retinol  [3–6].  One  of  these, 
lecithin:retinol acyltransferase (LRAT), catalyzes the transesterification of retinol employing a fatty 
acyl  group  present  in  the  A1  position  of  a  membrane  phosphotidyl  choline  molecule.  The  other,  
acyl-CoA:retinol  acyltransferase  (ARAT),  catalyzes  the  fatty  acyl-CoA-dependent  esterification  of 
retinol.  Studies  by  O’Byrne  et  al.  of  LRAT-deficient  mice  established,  for  mice  receiving  a Nutrients 2011, 3  
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physiologic  dose  of  retinol  (6  µ g),  that  LRAT-catalyzed  retinol  esterification  accounted  for 
approximately 90% of intestinal retinyl ester formation [39]. Chylomicrons isolated from the dosed 
LRAT-deficient mice contained some retinyl ester, which was presumably synthesized by an intestinal 
ARAT, and relatively high levels of the free alcohol retinol, which were not observed in chylomicrons 
obtained  from  WT  mice.  Subsequent  studies  by  Wongsiriroj  et  al.  established  that  the  enzyme 
diacylglycerol acyltransferase 1 (DGAT1), which catalyzes triglyceride synthesis from diacylglycerol 
and fatty acyl-CoA, acts as a physiologically significant ARAT in the mouse intestine [40]. Normally, 
for a physiological dose of retinol, DGAT1 accounts for approximately 10% of the retinol esterified in 
the intestine. However, the contribution that DGAT1 makes to intestinal retinol esterification becomes 
considerably greater upon administration of a large pharmacologic dose of retinol (1000 µ g) [40]. 
Under  physiologic  conditions,  LRAT  and  DGAT1  account  for  all  retinol  esterification  within  the 
enterocyte since no retinyl esters could be detected in chylomicrons isolated from LRAT/DGAT1-double 
knockout mice given a physiologic dose of retinol. However, when LRAT/DGAT1-double knockout 
mice  were  administered  a  pharmacologic  dose  of  retinol,  some  retinyl  ester  could  be  detected  in 
chylomicrons isolated from these mice, indicating the existence of other minor ARAT activities that 
can become active in response to excessive retinol intake [40]. In summary, LRAT accounts for the 
great majority of retinyl ester formed in the enterocyte upon consumption of normal dietary levels of 
retinoid; DGAT1, an intestinal ARAT, accounts for the remaining esterification activity.  
2.2.5. Cellular Retinol-Binding Protein, Type II (CRBPII)  
Retinoids are very insoluble in water and consequently within the aqueous environment of the body 
they are usually found bound to specific retinoid-binding proteins (see Table 1 below for a listing of 
retinoid-binding proteins). In the adult, CRBPII is reported to be expressed solely in the intestinal 
mucosa  and  is  proposed  to  facilitate  optimal  retinol  absorption  from  the  diet  [41].  Within  the 
enterocyte,  CRBPII  represents  0.4–1.0%  of  the  total  cytosolic  protein  [42].  To  investigate  the 
physiological role of CRBPII, Li and colleagues generated and studied CRBPII-deficient mice [43]. 
When maintained on a retinoid-enriched diet, the knockout mice were found to have reduced (by 40%) 
hepatic retinoid stores, but the mutant mice grew and reproduced normally. However, when maternal 
dietary retinoid levels were reduced to marginal levels during the latter half of gestation, a 100% 
mortality  rate,  within  24  hours  after  birth,  was  observed  for  these  litters  [43].  These  studies 
convincingly demonstrate that CRBPII acts to ensure adequate delivery of retinol to the developing 
fetus when dietary retinoid is limiting. Subsequent investigations making use of CRBPII-deficient 
mice bred into the LRAT-deficient background (lacking both CrbpII and Lrat) established that CRBPII 
metabolically channels retinol to LRAT for retinyl ester synthesis [40]. However, it could not be 
demonstrated experimentally that CRBPII directly prevents retinol from being acted upon in vivo by 
intestinal DGAT1 or other intestinal ARAT activities, as had been proposed in the older literature [4–6]. 
3. Chylomicrons and Their Metabolism in the Circulation 
For uptake of dietary retinoid, retinyl ester is packaged along with other dietary lipids into nascent 
chylomicrons,  which  are  secreted  into  the  lymphatic  system  [3–6].  As  mentioned  above,  dietary 
carotenoid  that  has  not  undergone  conversion  to  retinoid  is  also  incorporated  into  the  nascent Nutrients 2011, 3  
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chylomicrons.  After  entering  the  general  circulation,  the  nascent  chylomicrons  undergo  a  process  
of remodeling that involves primarily the hydrolysis of triglyceride by lipoprotein lipase (LpL) and  
the  acquisition  of  apolipoprotein  E  (apoE)  from  the  circulation,  resulting  in  the  formation  of 
chylomicron remnants. 
Table 1. Retinoid-binding proteins in the adult mouse 
a. 
Protein 
Other 
Designations 
Protein 
Family 
Major Retinoid 
Ligands 
Tissue Localization 
RBP  RBP4  Lipocalin  all-trans-retinol 
Many, with high levels in liver 
and adipose 
IRBP  RBP3  − 
all-trans-retinol 
11-cis-retinal 
Retina 
CRBPI  RBP1  iLBP 
all-trans-retinol 
all-trans-retinal 
Many, with high levels in liver, 
kidney, testis, eye, lung 
CRBPII  RBP2  iLBP 
all-trans-retinol 
all-trans-retinal 
Small intestine 
CRBPIII  RBP7  iLBP  all-trans-retinol  Heart, muscle, adipose, mammary 
CRABPI  RBP5  iLBP  all-trans-retinoic acid 
Ubiquitous expression, with high 
levels in brain, skin and testes 
CRABPII  RBP6 
b  iLBP  all-trans-retinoic acid 
Primarily skin; also found in 
mammary, uterus, kidney, 
prostate and olfactory epithelium 
CRALBP  RLBP1  CRAL_Trio 
11-cis-retinal 
11-cis-retinol 
9-cis-retinal 
RPE, retina, ciliary body, cornea, 
pineal gland, optic nerve, brain 
a  The  nomenclature  for  the  retinoid-binding  proteins  in  the  literature  is  inconsistent  between 
species. Thus, for clarity, this table contains alternative names for each protein in the adult mouse 
only. Alternative names may be different in other species, such as rat and human;  
b  Only  human  CRABPII  is  designated  RBP6;  mouse  CRABPII  is  not  referred  to  as  RBP6. 
Currently, there is no mouse form of RBP6. 
It has long been established that 66–75% of dietary retinoid (chylomicron and chylomicron remnant 
retinoid) is taken up by the liver where it is stored in hepatic stellate cells (HSCs), with the remainder 
being  cleared  by  peripheral  tissues  [44].  However,  the  significance  of  this  early  observation  for 
understanding  retinoid  metabolism  has  been  greatly  underappreciated.  Many  general  reviews  and 
textbooks describe how tissues acquire needed retinoid as retinol bound to its specific binding protein, 
retinol-binding protein (RBP [45], also referred to as RBP4 in the literature). But these general texts 
often fail to consider the contribution that postprandial retinoids, present in chylomicrons and their 
remnants, make to tissue retinoid pools. Yet, 25–33% of all the dietary retinoid that is absorbed by the 
intestine  is  delivered  via  chylomicrons  and  their  remnants  to  tissues  other  than  the  liver.  The 
physiological importance of the postprandial retinoid delivery pathway is underscored by the general 
good health of humans who lack RBP [46], as well as RBP-deficient mice [47]. Both humans and mice 
that  lack  RBP  are  physiologically  normal.  Thus,  if  these  humans  or  animal  models  are  provided 
retinoid regularly, at normal levels in the diet, the postprandial retinoid delivery pathway is sufficient Nutrients 2011, 3  
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to meet tissue requirements for retinoid. It should be noted for completeness that the circulation also 
contains low levels of retinoic acid, which can contribute significantly to tissue retinoic acid pools [48]. 
The processes through which chylomicron/chylomicron remnant retinoid is absorbed by peripheral 
tissues are only now starting to be explored (see Section 5.2 below for more detail). LpL can hydrolyze 
retinyl ester present in chylomicrons, and it has been proposed that retinyl ester hydrolysis facilitates 
retinol uptake by peripheral tissues [49]. For many tissues, there is now growing evidence that LpL 
facilitates  uptake  of  postprandial  retinoid  into  tissues.  Studies  involving  the  use  of  different 
perturbations to LpL activity and/or levels within tissues have established that LpL acts to modulate 
postprandial retinoid uptake by skeletal muscle, heart and adipose tissue [49,50], mammary tissue and 
milk [51,52], and probably lung [53]. 
4. Hepatic Retinoid Metabolism 
The liver is the major site of retinoid metabolism and storage in the body [3–6]. There are two 
hepatic cell types important to these processes: the parenchymal cells (also known as hepatocytes) and 
the stellate cells (also known as fat-storing cells, lipocytes, Ito cells, and perisinusoidal cells). The 
hepatocytes comprise approximately 66% of cells in the liver and contain 90% of the total protein 
mass  [54–56].  The  hepatic  stellate  cells  (HSCs)  are  relatively  much  smaller  and  less  abundant.  
The HSCs comprise only 6–8% of cells in the liver and contain 1% of hepatic protein [54–56]. It is 
well-established that hepatocytes are involved centrally in the uptake and processing of retinol in the 
liver, and that HSCs play a central role in hepatic retinoid storage. This section of the review will 
report  on  recent  advances  in  our  understanding  of  retinoid  metabolism  in  hepatocytes  and  HSCs, 
including the uptake and processing of chylomicron retinyl ester by the hepatocyte, transfer of retinoid 
to the HSC, storage of retinoid in the HSC and hepatic retinol mobilization.  
4.1. Uptake and Processing of Chylomicron Retinyl Ester by the Hepatocyte 
4.1.1. Hepatic Chylomicron Remnant Receptors  
When the retinyl ester-containing chylomicron remnant arrives at the liver, it passes into the space 
of Disse (located between the endothelium and the hepatocyte) in a process referred to as sieving [57]. 
Only  remnants  of  appropriate  size  can  pass  through,  while  larger  particles,  including  whole 
chylomicrons, are excluded. Once inside, the remnant is taken up exclusively by hepatocytes by one of 
two possible receptor-mediated pathways. The topic of receptor-mediated remnant uptake has been 
extensively and well reviewed by Cooper, and the reader is referred to this work for more detail [58]. 
Cooper  recounts  that  one  receptor-mediated  pathway  involves  direct  uptake  by  the  low  density 
lipoprotein (LDL) receptor, which has a high affinity for the apoE-rich chylomicron remnant particles, 
and internalization via endocytosis. If the LDL receptor is absent, down-regulated or saturated, the 
remnants may be sequestered in the space of Disse by binding to heparin sulfate proteoglycans (HSPGs), 
mediated by apoE. The remnants may also be sequestered through binding to hepatic lipase, which is 
enhanced by the presence of apoB. The remnants may eventually be transferred to LDL receptors as 
they become available or, if the remnants acquire enough apoE, transferred to an alternative receptor, 
the LDL receptor-related protein (LRP). LpL, acquired by the remnants during their formation, can Nutrients 2011, 3  
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facilitate uptake of remnants by LRP. It has not yet been established the extent to which each receptor 
contributes to chylomicron remnant-retinyl ester removal, but it likely depends on the metabolic state 
of the animal, which in turn can influence the amount of apoE being secreted.  
The importance of HSPGs in chylomicron remnant uptake was demonstrated by Zeng et al. who 
showed that remnant binding to the hepatocyte is dependent on both the expression of HSPG core 
proteins and the functionality of HSPG heparin sulfate chains [59]. Remnant binding in HepG2 cells 
was significantly decreased by antisense oligonucleotide knockdown of HSPG, antibodies to heparin 
sulfate,  heparinase  treatment  and  by  various  disruptions  of  the  heparin  sulfate  chains,  including 
inhibition of glycosylation. More recently, it’s been shown in vivo that the primary HSPG core protein 
involved in hepatic clearance of remnants is syndecan-1, which facilitates lipoprotein binding in the 
space of Disse [60].  
Though less understood, evidence for a third hepatic remnant uptake pathway is emerging. Studies 
in  normal  and  apoE-deficient  mice  fed  low-  or  high-fat  diets  showed  that  plasma  clearance  of 
chylomicron remnants is delayed with non-lipolyzed particles and is inhibited by lactoferrin, which 
blocks LRP [61]. When lipolysis was restored with the addition of hepatic lipase, no difference in 
uptake  was  observed  between  the  two  diet  groups  or  in  the  presence  and  absence  of  apoE.  This 
provided evidence for an apoE-independent pathway that functions through LRP. This idea was further 
investigated  by  Out  et  al.,  who  proposed  a  mechanism  involving  interactions  between  remnant 
phospholipids and a receptor on the surface of hepatocytes, SR-BI [62]. In SR-BI-deficient mice, 
triglyceride-rich  chylomicron-like  particles  associate  significantly  less  with  isolated  hepatocytes 
compared  to  WT  mice,  with  a  concomitant  delay  in  postprandial  triglyceride  clearance  [62]. 
Adenovirus-mediated  hepatic  overexpression  of  SR-BI  significantly  decreased  serum  cholesterol, 
phospholipids and TG [63]. While a role for SR-BI in chylomicron remnant metabolism in the liver is 
likely, it remains to be determined if and how it may interact with the other receptor systems.  
4.1.2. Retinyl Ester Hydrolysis in the Hepatocyte  
Upon entry into the hepatocyte, the retinyl ester is associated with early endosomes and undergoes 
rapid hydrolysis [64]. The hydrolysis of retinyl ester is carried out by a number of enzymes referred to 
in the literature as REHs, carboxylesterases and/or lipases.  
The first well-characterized REH was the bile salt-dependent CEL (see above for more details 
regarding CEL actions in the intestine), which is a potent bile salt-dependent REH in vitro [65,66]. 
Hepatic CEL was found to have very close similarity to pancreatic CEL in terms of mRNA sequence, 
enzymatic activity and antibody recognition [67]. Like pancreatic CEL, hepatic CEL is also a secreted 
enzyme, so it was first hypothesized to be involved in retinyl ester hydrolysis in the space of Disse [68]. 
However, it was shown that lack of CEL expression does not affect uptake of dietary chylomicron 
remnant-retinyl ester in the liver, and furthermore, the livers of CEL-deficient mice display similar 
REH activity compared to wild type livers [69]. The presence of REH activity in the liver distinct from 
CEL  was  confirmed  by  the  discovery  of  neutral,  bile  acid-independent  REH  activity  in  rat  liver 
homogenates that localized to the microsomal fraction, consistent with a role in retinyl ester hydrolysis 
in the plasma membrane and/or endosome, and was not cross-reactive with antibodies to the pancreatic 
enzyme [70]. It was later found that this activity was stimulated by the presence of apo-CRBPI at Nutrients 2011, 3  
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physiological concentrations, suggesting apo-CRBPI may be a regulator of retinyl ester hydrolysis 
in vivo [71]. Acidic bile salt-independent REH activity has also been observed in rat liver plasma 
membrane  and  endosomal  fractions  [72].  It  has  been  postulated  that  the  neutral  REH  acts  on 
chylomicron remnant-retinyl ester at the cell surface and when it enters the early endosome, and as the 
pH drops in the late endosome, retinyl ester hydrolysis is continued by the acidic REH [73].  
Another group of enzymes proposed to be important to retinyl ester hydrolysis in the liver is the 
carboxylesterases. Although over 30 liver carboxylesterases with various oxyester substrates have been 
identified, most of these enzyme activities are thought to arise as the gene products of five major loci 
in  linkage  group  V  and  are  referred  to  as  ES-2,  ES-3,  ES-4,  ES-10  and  ES-15  [74].  Of  these 
five enzymes, ES-2, ES-4 and ES-10 have been shown specifically to possess REH activity in the liver 
in vitro [75,76]. ES-4 functions primarily as a thioesterase to catalyze the hydrolysis of long-chain acyl 
Co-A [75], but it has also been shown to hydrolyze retinyl palmitate [77]. ES-2 and ES-10 have been 
shown to function as neutral bile salt-independent REHs. Sun et al. purified REH activity from rat 
liver microsomal fractions that reacted with antibodies against ES-2, showed substrate preference for 
retinyl palmitate and had a pH optimum of 7 [76]. Similarly, they were able to purify REH activity that 
corresponded  to  the  protein  size  and  amino  acid  sequence  of  ES-10  and  also  demonstrated 
immunoreactivity to antibodies directed against ES-10. More recently, ES-22 has been reported to be a 
hepatic REH. Schreiber et al. identified ES-22 as a hepatocyte-expressed esterase that localizes to the 
ER  [78].  These  investigators  showed  that  ES-22  specifically  hydrolyzes  retinyl  palmitate,  but  not 
triolein or cholesteryl oleate. Additionally, overexpression of ES-22 inhibited the accumulation of 
retinyl esters in COS-7 cells.  
A number of in vitro studies have also identified some well characterized lipases that possess REH 
activity, including hepatic lipase [79], LpL [49,50], PTL [9,10], and hormone sensitive lipase (HSL) [80]. 
Mello et al. have shown that, of these, only hepatic lipase and LpL are expressed in the liver (mRNA 
levels  of  PTL  and  HSL  in  all  liver  cell  types  were  very  low)  [81].  Hepatic  lipase  is  exclusively 
expressed in hepatocytes and is the only secreted lipase expressed in these cells [81]. It is secreted by 
the hepatocyte into the space of Disse, where it can function in the binding and uptake of chylomicron 
remnants and possibly in the hydrolysis of chylomicron remnant retinyl ester, though there is currently 
no direct evidence for the latter possibility. LpL is expressed at very low levels in hepatocytes and 
HSCs, but its expression is induced 32-fold in activated HSCs [81]. Thus, Mello et al. propose that it is 
unlikely LpL functions in the hydrolysis of newly absorbed hepatic chylomicron remnant-retinyl ester, 
but rather may have a role in the hydrolysis of lipid droplet retinyl esters in activated HSCs [81]. How 
this might occur is unclear, given that LpL is a secreted enzyme, and there is no evidence for it acting 
intracellularly. A summary of proposed REHs in hepatocytes can be found in Table 2.  
The  physiological  significance  of  the  many  lipid  hydrolases  and  carboxylesterases  in  the  liver 
remains to be indentified. However, this uncertainty is true for many other tissues in the body as well; 
in vivo retinyl ester hydrolase activity has only been determined for a number of these enzymes. For 
example, it is clear that PTL and PLRP2 are physiologically significant retinyl ester hydrolases in the 
intestine. As discussed in further detail below, LpL-catalyzed retinyl ester hydrolysis is important for 
facilitating postprandial retinol uptake into adipose tissue, heart and skeletal muscle. And similarly, it 
is known that HSL catalyzes retinyl ester hydrolysis in adipocytes to allow for retinol mobilization into 
the circulation. With these exceptions, the identities of most other physiologically significant retinyl Nutrients 2011, 3  
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ester  hydrolases  remain  obscure.  It  is  likely  that  several  other  enzymes  will  be  shown  to  have 
physiologically signifcant and distinct roles in catalyzing this reaction. With respect to the liver, we 
speculate that this may include hepatic lipase in hepatocytes and HSL in HSCs. Much work remains to 
elucidate  the  roles  of  these  many  enzymes  in  the  various  tissues  that  function  in  the  uptake  and 
metabolism of retinoid in the body. 
Table 2. Proposed Hepatic Retinyl Ester Hydrolases (REHs). 
Protein  Hepatic Cell Type 
Bile salt-dependent REH 
(identified to be CEL) 
Hepatocyte 
Neutral, Bile salt-independent REH  Hepatocyte 
Acidic, Bile salt-independent REH  Hepatocyte 
ES-2  Hepatocyte 
ES-4  Hepatocyte > HSC 
ES-10  Hepatocyte > HSC 
ES-22  Hepatocyte 
Hepatic Lipase  Hepatocyte 
LpL  HSC (activated) 
ATGL  HSC 
4.2. Transfer of Retinol from Hepatocytes to HSCs 
After  the  chylomicron  retinyl  ester  is  hydrolyzed  to  retinol  within  the  hepatocyte,  it  is  then 
transferred  to  the  HSC  where  it  is  re-esterified  and  stored  in  lipid  droplets.  This  transfer  occurs 
primarily in times of sufficient or excess retinoid intake, so that these retinoid stores may be called 
upon and mobilized in times of vitamin A deficiency. The mechanism of transfer has not been the 
focus of more recent research and thus, is not fully understood. A couple of possibilities exist and are 
discussed below.  
4.2.1. RBP-Mediated Transfer  
Early studies suggested that this transfer is mediated by retinol-binding protein (RBP). Blomhoff et al. 
reported that antibodies against RBP completely blocked the transfer of retinol from hepatocytes to 
HSCs [82]. Following loading of hepatocytes in vivo by intravenous injection of [
3H]retinyl ester-labeled 
chylomicrons, livers were perfused in situ with either a control buffer or a buffer containing an excess 
of  antibodies  against  RBP.  In  both  groups,  the  radioactivity  recovered  10  min  after  loading  was 
significantly higher in hepatocytes than in HSCs; after 40 min of perfusion, the control group showed 
significantly higher 
3H-cpms associated with the HSCs, while the HSCs from the livers perfused with 
the RBP antibodies still had less 
3H-cpms than hepatocytes. A similar study by Senoo et al. showed 
that  antibodies  to  RBP  blocked  its  transfer  from  HepG2  cells  to  rat  HSCs,  when  the  cells  were  
co-cultured [83]. This study also showed that RBP could be internalized by cultured HSCs when the 
cells were incubated with human RBP. RBP was first observed to be associated with vesicles close to 
the cell surface and membrane and was later found deeper in the cytoplasm within endosomes. The Nutrients 2011, 3  
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findings that RBP is able to be bound and internalized by HSCs and that antibodies to RBP inhibited 
transfer of retinol into HSCs was taken to suggest that RBP mediates this transfer.  
However, the generation of RBP-deficient mice allowed this hypothesis to be tested directly, and 
the results are not in agreement with these earlier proposals. Quadro et al. showed that, in 3- and 
13-week-old mice, there is no statistical difference in hepatic total retinol levels between WT and 
RBP-deficient mice; thus, the absence of RBP does not impair hepatic uptake of retinol [47]. It was 
later demonstrated that there is no quantitative or qualitative differences in the lipid droplets present in 
liver sections from RBP-deficient compared to WT mice, suggesting that retinol transfer to HSCs for 
storage is unaffected by the absence of RBP [84]. These studies provide strong evidence that RBP does 
not act in an essential manner in the transfer of retinol from hepatocytes to HSCs.  
4.2.2. CRBPI-Mediated Transfer  
The  involvement  of  CRBPI  in  the  transfer  process  has  been  suggested  by  data  from  
Ghyselinck et al. [85], whose studies of CRBPI-deficient mice suggest that CRBPI may mediate the 
transfer  of  retinol  from  hepatocytes  to  HSCs  [85].  CRBPI-deficiency  was  found  to  result  in 
significantly lower hepatic retinyl ester levels, with mutant mice having a 50% reduction in levels of 
retinyl palmitate, the main retinyl ester form found in the liver. Light microscopy also revealed that the 
HSCs of CRBPI-deficient mice are characterized by a reduction in both the number and size of lipid 
droplets. This suggests a decrease in retinyl ester synthesis that likely occurs due to impaired delivery 
of retinol to the retinyl ester-synthesizing enzyme LRAT, which is highly expressed in HSCs [86]. 
These studies clearly indicate that CRBPI is necessary for assuring efficient retinol esterification and 
storage in vivo. Future studies are needed to confirm how the presence and absence of CRBPI affects 
total retinol levels specifically in hepatocytes and HSCs.  
4.3. Storage of Retinoid in the HSC as Retinyl Ester in Lipid Droplets  
4.3.1. The role of HSC Lipid Droplets in Retinoid Storage  
The most distinguishing feature of the HSC is the presence of numerous retinyl ester-containing 
lipid droplets in the cytoplasm, which have recently been proposed to be specialized organelles for 
retinoid storage [86]. This idea arises from numerous studies showing the unique retinoid content of 
these droplets, their responsiveness to dietary retinoid status, their dependence on the synthesis of 
retinyl ester, and their loss in different types of hepatic disease. Taken together, these studies have 
demonstrated  a  strong  regulatory  role  of  retinoids  in  HSC  lipid  droplet  physiology.  This  will  be 
discussed below in more detail. 
4.3.2. Esterification of Retinol in the HSC  
After transfer from the hepatocyte to the HSC, retinol is esterified back to retinyl ester for storage in 
HSC  lipid  droplets.  Once  in  the  HSC,  retinol  is  bound  by  CRBPI  and  transferred  to  LRAT  for 
esterification  [87].  The  binding  of  retinol  to  CRBPI  is  necessary  for  its  transport  in  the  aqueous 
environment of the cytosol and has been proposed to prevent acyl CoA-dependent enzymes in the liver Nutrients 2011, 3  
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from catalyzing retinyl ester formation [87]. Both LRAT and CRBPI are enriched in HSCs [5,6,86], 
and both proteins are needed to assure optimal HSC accumulation of retinoid stores.  
LRAT is the only known enzyme capable of esterifying retinol in the liver in vivo. Earlier in vitro 
studies  suggested  that an  unidentified  ARAT(s)  may  work in conjunction with  LRAT to  catalyze 
retinyl ester formation [88]. As mentioned above, DGAT1 has been shown to participate in retinol 
esterification in vitro [39,89,90] and in the intestine and skin in vivo [40,91]. Thus, DGAT1 became a 
candidate for in vivo esterification of retinol in the liver, as well. However, the generation and study of 
LRAT-deficient  mice  fail  to  support  both  possibilities.  O’Byrne  et  al.  show  that  the  livers  of  
LRAT-deficient  mice  have  undetectable  levels  of  retinyl  ester  and  are  completely  void  of  lipid 
droplets [39]. These studies not only proved that LRAT is the only retinol esterifying enzyme present 
in the liver, but also that LRAT and/or its product retinyl ester is necessary for HSC lipid droplet 
formation. Around the same time, Liu and Gudas reported that disruption of the Lrat gene makes mice 
more  susceptible  to  retinoid-deficiency  [92].  After  maintenance  on  a  retinoid-deficient  diet  for 
six weeks,  LRAT-deficient  mice  had  significantly  lower  serum  retinol  levels  than  WT  mice  and 
undetectable levels of retinol in a number of tissues studied, including the liver. Thus, Liu and Gudas 
proposed that LRAT-deficient mice may serve as a readily inducible, and hence useful, model to study 
retinoid-deficiency [92]. 
4.3.3. HSC Lipid Droplet Content and Effects of Dietary Retinoid Status  
Moriwaki et al. reported the lipid composition of lipid droplets isolated from primary rat HSCs [93]. 
In rats maintained on a control diet, the mean percent lipid composition consisted approximately of 
40%  retinoid  lipid  and  60%  non-retinoid  lipid,  broken  down  as  follows:  39.5%  retinyl  ester, 
31.7% triglyceride, 15.4% cholesteryl ester, 6.3% phospholipid, 4.7% cholesterol and 2.4% free fatty 
acids. The retinyl esters present in these droplets possess only long chain fatty acyl moieties, with 
retinyl palmitate followed in abundance by retinyl stearate, retinyl oleate and retinyl linoleate [94]. 
In the same study, the rats were maintained on four additional experimental diets containing either low 
or high retinol and low or high triglyceride. The investigators found that HSC lipid droplet retinyl 
esters, as well as other lipids, are decreased in response to a low retinol diet, and both retinoid and 
non-retinoid  lipids  are  elevated  in  response  to  a  high  retinol  diet;  however,  neither  retinoid  nor 
non-retinoid content is affected by low or high fat diets. This data was taken to indicate that the lipid 
composition of HSC lipid droplets is strongly influenced by dietary retinoid status, but not by dietary 
triglyceride intake. 
4.3.4. HSC Lipid Droplets in Hepatic Disease  
Following acute liver injury, a wound healing response is initiated, which ultimately returns the 
liver to its healthy state [54–56]. However, when the liver is confronted with chronic injury, the result 
is often hepatic fibrosis, which is the formation of excess fibrous connective tissue as a reparative 
process to contain the site of injury. The most common causes of hepatic fibrosis include chronic 
hepatitis B and C infection, alcoholism, non-alcoholic fatty liver disease (NAFLD), and bile duct 
obstruction.  Further  progression  of  disease  will  lead  to  cirrhosis  and  eventually  hepatocellular 
carcinoma. Seminal work by Leo and Lieber established that with this progression of liver disease in Nutrients 2011, 3  
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human subjects is the progressive depletion of hepatic retinoid [95]. These investigators found that 
there is a near 5-fold decrease in total hepatic retinol levels with the development of alcoholic hepatitis 
and another approximate 4-fold decrease with the development of cirrhosis. It remains unclear whether 
this loss of hepatic retinoid content is a causative agent or simply a consequence of disease. 
As  a  result  of  injury,  HSCs  undergo  a  process  of  activation  in  which  they  transition  from  a 
quiescent state to a myofibroblastic phenotype [96,97]. Activated HSCs are characterized by increased 
synthesis of extracellular matrix and thereby become fibrogenic and proliferative [96,97]. There are 
currently several in vivo models of HSC activation, including carbon tetrachloride injection and bile 
duct ligation, and one commonly studied in vitro model, the culture of primary HSCs on plastic.  
It has been demonstrated that the changes in gene expression that accompany HSC activation and the 
loss of HSC retinyl ester lipid droplets are regulated differently in the in vitro model and the in vivo 
models [98]. Thus, the study of HSC activation can only be studied in the context of the disease  
model employed.  
Two hypotheses have been proposed to account for the loss of retinyl ester lipid droplets in hepatic 
disease. One theory is that HSC activation results in a ―toxic burst‖ of transcriptionally active retinoids 
from  the  lipid  droplet  stores  and,  acting  through  the  retinoic  acid  receptors  and  the  retinoid  X  
receptors (all of which are expressed in HSCs), lead to the altered gene expression patterns seen with 
activation [99,100]. The other proposes that the retinoid stores in these lipid droplets play a protective 
role,  such  that  their  presence  buffers  against  hepatic  insult  [101].  When  these  stores  are  absent,  
an injury to the liver will result in fibrosis and hepatic disease. This second hypothesis seems unlikely 
considering LRAT-deficient mice are not predisposed to developing spontaneous hepatic fibrosis [39]. 
However, more definitive studies need to be conducted before the linkage between the loss of HSC 
retinoid stores and hepatic disease can be determined. 
4.4. Mobilization of Retinol from Hepatic Stores to Peripheral Tissues 
4.4.1. Hydrolysis of HSC Lipid Droplet Retinyl Ester  
As mentioned above, HSC lipid droplet retinyl ester stores must be mobilized in times of dietary 
retinoid-insufficiency  to  supply  peripheral  tissues  with  retinoid  needed  for  maintaining  various 
essential biological functions. Mobilization requires that the retinyl ester first be hydrolyzed back to 
retinol. It is currently not known which lipases are involved in the hydrolysis of HSC retinyl ester, but 
there are several candidate  enzymes  based on their  REH activity and/or  expression in  HSCs  (see 
Table 2). As discussed above, ES-2, ES-4 and ES-10 are three hepatic carboxylesterases shown to have 
REH activity [75,76]. Mello et al. show that ES-4 and ES-10 are expressed in HSCs, albeit at very low 
levels compared to hepatocytes [81]. Their REH activity and expression in HSCs make ES-4 and ES-10 
strong candidates for HSC lipid droplet retinyl ester hydrolases. Another candidate for HSC retinyl 
ester  hydrolysis  is  adipose  triglyceride  lipase  (ATGL).  ATGL  is  the  key  enzyme  for  triglyceride 
hydrolysis  in  adipocytes  [102],  and  its  lipase  activity  in  vivo  is  dependent  on  coactivation  by 
CGI-58 [103]. Earlier studies suggested ATGL does not have REH activity, but these studies were 
done in the absence of CGI-58 [102]. Mello et al. found that ATGL is expressed highly in HSCs and Nutrients 2011, 3  
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propose that, in the presence of CGI-58, will have REH activity [81]. However, this possibility has not 
yet been demonstrated directly.  
4.4.2. Role of RBP in Hepatic Mobilization of Retinol  
Upon hydrolysis of HSC lipid droplet retinyl ester, retinol is thought to be transferred back to the 
hepatocyte, where it is bound by its specific transport protein, RBP. RBP is a 21 kDa protein with a 
single binding site for one molecule of all-trans-retinol, and the hepatocyte is the major (though not 
exclusive) site of RBP synthesis in the body [104]. Once bound by RBP, the retinol-RBP complex 
enters the bloodstream for transport to peripheral tissues. Secretion of RBP by the hepatocyte is highly 
regulated by the retinoid status of the animal, such that RBP secretion is blocked in times of dietary 
deficiency and restored upon retinol-repletion [105].  
The  importance  of  RBP  in  maintaining  retinoid  homeostasis  in  the  body  was  demonstrated by 
Quadro et al. through generation of RBP-deficient mice [47]. These investigators show that, in 3- and 
13-week-old mice, there is no statistical difference in hepatic total retinol levels between WT and  
RBP-deficient mice; thus, the absence of RBP does not impair hepatic uptake and accumulation of 
retinol. However, when these investigators measured hepatic and serum retinol levels in 5-month-old 
mice, they found that hepatic retinol and retinyl ester levels were significantly higher in RBP-deficient 
compared to WT mice and, additionally, serum total retinol levels were significantly lower. These data 
indicate that RBP-deficient mice can acquire hepatic retinol stores, but these cannot be mobilized.  
It was later shown using transgenic mice that express human RBP that extrahepatically synthesized 
RBP cannot be taken up by hepatocytes and cannot function in the mobilization of hepatic retinol 
stores [84]. Only RBP synthesized in the liver can mobilize hepatic retinol stores. 
In  the  blood,  RBP  is  found  in  a  1:1  protein-protein  complex  with  a  55  kDa  serum  protein, 
transthyretin  (TTR)  [104].  The  retinol-RBP-TTR  complex  is  the  predominant  transport  molecule 
through which retinol is delivered to peripheral tissues in the fasting circulation. In the absence of 
TTR, plasma retinol and RBP levels are only approximately 5% of those that are observed in matched 
WT mice [104]. It has been established that the association of RBP with TTR prevents filtration of the 
relatively small RBP molecule through the kidney glomeruli [106]. Studies by van Bennekum et al. 
employing  TTR-deficient  mice  have  demonstrated  the  importance  of  TTR  in  maintaining  normal 
levels  of  retinol  and  RBP  in  the  circulating  plasma.  Subsequent  studies  established  that,  when  a 
physiologic dose of human retinol-RBP was injected intravenously into TTR-deficient mice, it was 
cleared more rapidly from the plasma and accumulated more rapidly in the kidneys of TTR-deficient 
than WT mice [106]. These data were taken by the authors to indicate that the reduced levels of retinol 
and RBP in the circulations of TTR-deficient mice arise, at least in part, due to increased filtration of 
the retinol-RBP complex. Other studies of TTR-deficient mice showed that the livers of these mutants 
have similar levels of retinol and retinyl ester compared to WT mice, but 60% higher levels of RBP 
protein  [107].  These  data  indicated  that  TTR  does  not  have  a  role  in  hepatic  uptake  or  storage  
of  dietary  retinol,  but  suggested  it  may  play  a  role  in  hepatic  secretion  of  RBP.  However,  
van Bennekum et al. were unable to establish directly that the absence of TTR affects RBP secretion 
from hepatocytes [106]. These investigators showed that cultured primary hepatocytes isolated from 
TTR-deficient mice accumulated RBP in their culture media to the same degree as hepatocytes from Nutrients 2011, 3  
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WT mice; thus, RBP was being secreted from hepatocytes at the same rate in the presence and absence 
of TTR.  
5. Uptake of Retinoids by Extrahepatic Tissues 
In the fasting state, >95% of retinoid in the circulation is found as retinol bound to RBP (i.e., as 
retinol-RBP). The remainder of circulating retinoid in the fasting circulation is comprised of a variety 
of  low  abundance  species,  including  retinyl  esters  associated  with  lipoproteins  (very  low  density 
lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL)) and retinoic 
acid  bound  to  albumin.  In  the  postprandial  state,  chylomicron  retinyl  ester  is  elevated  and  can 
quantitatively predominate over retinol-RBP [6]. In this section, recent advances in our understanding 
of how retinol-RBP is taken up in extra-hepatic tissues will be discussed, as well as insights into 
mechanisms associated with the uptake of retinol from postprandial, chylomicron-remnant derived, 
retinyl ester (as summarized in Figure 3 below). 
Figure  3.  Uptake of retinoids into extrahepatic tissues. Retinoids in the circulation are 
present  in  several  forms,  including  retinol  bound  to  RBP  (holo-RBP),  retinyl  esters  in 
lipoproteins (primarily chylomicrons, but also VLDL, LDL, and HDL), and retinoic acid 
bound  to  albumin.  The  mechanisms  that  mediate  cellular  uptake  of  retinyl  ester  and 
retinoic acid are not fully understood. However, it has been established for certain tissues 
that LpL can hydrolyse retinyl ester to retinol, which can then be taken up by  tissues  
and cells. The transmembrane protein STRA6 is able to bind holo-RBP and facilitate its 
uptake into cells. 
 
5.1. Uptake of Retinol-RBP from the Blood by Extrahepatic Tissues 
While  the  spontaneous  transfer  of  free  retinol  across  the  phospholipid  bilayer  is  a  possibility 
supported  by  experimental  evidence,  the  existence  of  a  cell-surface  receptor  for  RBP  has  been Nutrients 2011, 3  
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postulated  since  the  mid-1970s  (as  extensively  summarized  in  [6]).  In  2007,  Kawaguchi  et  al. 
identified and studied a transmembrane-spanning protein STRA6 (stimulated by retinoic acid 6) that 
acts  as  a  receptor  for  RBP  in  many,  but  not  all,  tissues  (since  it  is  not  expressed  in  all  retinoid 
metabolizing tissues) [108]. These authors demonstrated that (i) RBP can bind to STRA6 with high 
affinity, (ii) STRA6-transfected cells efficiently take up retinol, especially if LRAT is expressed within 
the cells, (iii) RNAi knockdown of STRA6 suppresses retinol uptake, and (iv) STRA6 is expressed in 
tissues consistent with its function as an RBP receptor. These experiments provide strong evidence that 
STRA6 can function as an RBP receptor and mediate the cellular uptake of retinol. Interestingly, a 
synergy exists between STRA6 and LRAT expression, such that cells expressing both proteins uptake 
relatively more retinol than cells expressing either protein individually [108,109]. This phenomenon 
indicates that conversion of retinol into retinyl ester by LRAT within the cell maintains the driving 
force for STRA6-mediated retinol uptake. This suggests a model whereby circulating retinol-RBP 
binds to STRA6 located on the cell surface, facilitating uptake of retinol and its conversion to retinyl 
ester by LRAT.  
The  concept  of  STRA6-mediated  cellular  uptake  of  retinol  has  been  extended  to  include  
STRA6-mediated efflux of retinol from the cell by von Lintig and colleagues. Cell culture experiments 
have shown that STRA6-expressing cells, preloaded with retinol, release more retinol into the culture 
medium than cells which do not express STRA6, a process which is RBP-dependent [109]. In vivo 
evidence  of  STRA6-mediated  retinol  efflux  comes  from  observations  made  in  the  developing  
mouse embryo [110]. Embryonic STRA6 expression is upregulated in response to maternal dietary 
retinoid-excess. Similarly, STRA6 levels were elevated in  LRAT-deficient mouse embryos, where 
intracellular retinol levels would be higher because of the incapacity to convert retinol to retinyl ester. 
These data are interpreted to indicate that STRA6 is upregulated to facilitate export of excessive levels 
of retinol from the cell [110]. These findings suggest that STRA6 acts as a bidirectional transporter of 
retinol, with intracellular retinol concentrations determining the polarity of transport. 
The  notion  that  STRA6  acts  as  a  bidirectional  retinol  transporter  is  attractive  as  it  resolves  a 
theoretical paradox with regard to STRA6 expression [111]. If one accepts that STRA6 facilitates 
retinol uptake and that its expression is stimulated by retinoic acid, then in times of excess retinoic 
acid, STRA6 expression would increase and drive more potentially toxic retinoid into the cell. This 
detrimental scenario is avoided if we accept that STRA6 also facilitates retinol export. Here, excess 
retinoic acid and the associated increase in STRA6 would channel retinol out of the cell, thereby 
protecting it. It is possible that STRA6 functions at a basal level to import retinol into the cell to 
maintain  intracellular  retinoid  homeostasis,  and  in  times  of  retinol  excess  within  the  cell  it  can  
be upregulated and function in retinol export, protecting the cell from a potentially cytotoxic build  
up of retinoid. 
The hypothesis that STRA6 expression is driven by retinoic acid is supported by studies in several 
cell  lines  [112–115].  But  data  from  in  vivo  measurements  of  STRA6  expression  are  not  in  good 
agreement.  High  maternal  dietary  retinoid  intake  is  associated  with  increased  embryonic  STRA6 
expression [110], and retinoic acid has been shown to increase STRA6 expression in the lungs of 
neonatal rats [116]. However, these data conflict with observations from chick embryos, in which 
retinoic acid soaked beads had no effect on STRA6 expression [117]. If we consider the opposite 
extreme of retinoid nutriture, the data are also contradictory. Mouse embryos from dams deprived of Nutrients 2011, 3  
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dietary  retinoid  showed  no  change  in  STRA6  expression  [110],  whereas  retinoid-deficient  quail 
embryos upregulate STRA6 [117]. It is likely that control of STRA6 expression is tightly regulated at 
both the gene and protein levels, and depends on the cellular context and retinoid status of the animal.  
Irrespective of debate regarding the physiological function of STRA6, a role in cellular retinoid 
homeostasis is pointed to by the severe congenital abnormalities associated with STRA6 mutations in 
humans. Postulated loss-of-function mutations in STRA6 have been found in more than 20 individuals 
with syndromic anophthalmia/microphthalmia, in association with variable malformations of the heart, 
lungs, and diaphragm (Microphthalmic syndrome 9, OMIM 601186) [118–125]. Significantly, retinoid 
signaling  is  known  to  be  important  in  the  development  of  the  eye  [126,127],  lungs  [128,129], 
heart [130,131],  and  diaphragm  [132,133].  Further,  malformations  in  these  tissues  are  commonly 
found as part of the maternal retinoid-deficiency syndrome [134]. The parallel between the effects of 
maternal retinoid-deficiency and STRA6 mutation supports the concept that STRA6 is  needed for 
maintaining cellular retinoid homeostasis during organogenesis. Interestingly, there is a discrepancy 
between the severe outcome of STRA6 mutation in humans, and mutations of RBP, which yield only a 
mild  clinical  phenotype  [46,47],  leading  some  authors  to  speculate  that  STRA6  may  have  other 
unknown functions in addition to it being an RBP receptor [111].  
5.2. Extrahepatic Uptake of Chylomicron Retinyl Ester 
As mentioned above, nascent chylomicrons from the intestine are rapidly metabolized in the general 
circulation,  yielding  smaller  lipoprotein  particles  called  chylomicron  remnants.  It  has  been  well 
established that while ~75% of postprandial retinyl ester is taken up by the liver, the remaining ~25% 
is taken up by extra-hepatic tissues, including white adipose tissue, skeletal muscle, heart, lungs, and 
kidneys [44,50,69]. The physiological importance of postprandial retinyl ester uptake into extra-hepatic 
tissues was initially unclear; however, a growing body of evidence suggests that this source can be an 
important factor in maintaining retinoid homeostasis in specific tissues. 
A physiologic role for uptake of postprandial retinyl ester was highlighted in mice lacking RBP [47]. 
Despite  having  only  trace  levels  of circulating retinol  and having  an  impaired ability  to  mobilize 
hepatic retinol, RBP-deficient mice are viable and fertile. These mice do have a transient visual defect, 
though this resolves with age (a further expansion of the RBP-deficient phenotype is provided below). 
The relatively benign phenotype of these mice led the authors to hypothesize that retinoid homeostasis 
was being maintained by uptake of postprandial retinoid. Investigation of RBP-deficient mice revealed 
that  the  mutant  mice  have  a  relatively  high  concentration  of  circulating  retinyl  ester  in  the 
chylomicron/VLDL plasma fraction, supporting the hypothesis that chylomicron-derived retinyl esters 
were important in maintaining their good health [135]. It was also found that the eye is particularly 
poor at taking up chylomicron-derived retinyl ester; this suggests why vision was impaired in these 
animals,  whereas  other  organ  systems  were  unaffected  because  of  their  ability  to  readily  uptake 
postprandial retinyl ester [136]. Study of RBP-deficient mice also indicated that these mice can use 
postprandial retinyl ester to support normal embryogenesis [135]. This concept was investigated in 
more  depth  showing  that  retinyl  ester  is  important  for  the  establishment  of  fetal  retinoid  stores, 
whereas retinol-RBP has a more direct role in embryogenesis and organogenesis [137].  Nutrients 2011, 3  
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The contribution of postprandial retinyl ester uptake has also been studied in other tissues. In the 
lactating  mammary  gland,  a  contribution  of  retinyl  ester  into  milk  retinoid  has  been  shown  in 
non-human primates and rodents [51,138–140]. The magnitude of this contribution is thought to reflect 
dietary retinoid intake, such that with increasing levels of retinoid consumed in the diet, the proportion 
of chylomicron-derived retinyl ester in the milk relative to retinol-RBP, also increases. In the extreme, 
it has been shown that chylomicron retinyl ester uptake can completely compensate for RBP-deficiency 
in  mammary  tissue,  such  that  the  retinoid  content  of  milk  in  RBP-deficient  mice  is  identical  to  
age- and diet-matched WT mice [52]. Another tissue in which the contribution of postprandial retinyl 
ester uptake is thought to be important is the lung [53]. Studies in rats have shown that the retinoid 
content of the lung is reduced in 9-week-old rats that were raised on a retinoid-deficient diet. Neonatal 
retinoid supplementation of these animals was sufficient to normalize serum and liver retinoids levels, 
but lung levels remained low. This finding can be interpreted to indicate that the lung requires a direct 
contribution of postprandial retinoid to accumulate retinoid stores, presumably from chylomicrons [53]. 
In addition to understanding the physiological significance of postprandial retinyl ester uptake, the 
biochemical mechanisms involved are  of interest. It was hypothesized in  the  mid-1990s  that LpL  
may have a physiological role in the hydrolysis of chylomicron retinyl ester, thereby facilitating its  
uptake [49]. In a series of in vitro experiments, these authors demonstrated that LpL can catalyze the 
hydrolysis of retinyl ester in its four most abundant forms (retinyl palmitate, retinyl oleate, retinyl 
stearate, and retinyl linoleate). Triglycerides were the preferred substrate for LpL, though when the 
majority of triglycerides were hydrolyzed (~75%), retinyl ester hydrolysis was observed. Also, the 
inclusion of apolipoprotein C-II, a known LpL activator [141], further enhanced the LpL-catalyzed 
hydrolysis of retinyl ester. These experiments, coupled with the observation that hydrolysis of retinyl 
ester to retinol by LpL was associated with increased retinoid uptake by BFC-1β adipocytes, strongly 
suggested that LpL may have a physiological role in the extrahepatic uptake of retinoid [49]. These 
authors further concluded that uptake of retinol into adipocytes was not receptor mediated [49]. In vivo 
evidence  in  support  of  this  hypothesis  came  from  experiments  in  which  the  tissue  levels  of  LpL 
expression were experimentally manipulated [50]. Specifically, mice over-expressing LpL in skeletal 
muscle show increased uptake of chylomicron retinoid into their skeletal muscle. Similarly, double-mutant 
mice, over-expressing human LpL in skeletal muscle, but containing a null mutation in the murine LpL 
gene, show decreased levels of uptake in the heart. In another series of experiments, LpL activity was 
modulated in rats by fasting. In the fasting rat, adipose tissue LpL activity is decreased, and heart and 
skeletal muscle activity is increased. Accordingly, fasted animals had decreased retinyl ester uptake in 
the adipose tissue and increased uptake in the heart and skeletal muscle, relative to control. A further 
dissection  of  LpL-facilitated  uptake  of  chymomicron  retinyl  ester  in  the  heart  has  recently  been 
undertaken [142]. These authors show that uptake of chylomicron derived retinyl ester is significantly 
reduced in mice with a heart-specific deletion of LpL. Uptake was unaffected in CD36 knock-out mice 
and LpL/CD36 double knock-out mice, suggesting that this fatty-acid transporter is not essential for 
retinol uptake into the heart. Taken together these results indicate that, at least in skeletal muscle, 
heart, and adipose tissue, LpL expression and activity closely reflect the tissue’s ability to take up 
chylomicron  retinyl  ester,  such  that  increased  expression  is  associated  with  increased  uptake,  and 
vice versa.  Interestingly,  while  LpL  appears  to  facilitate  chylomicron  retinyl  ester  uptake  in  these  
tissues, other tissues which take up postprandial retinyl ester were unaffected by manipulations of  Nutrients 2011, 3  
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LpL  expression/activity,  such  as  the  kidneys  and  lungs.  This  indicates  that  an  unidentified, 
LpL-independent mechanism, exists to mediate the extra-hepatic uptake of chylomicron retinyl ester. 
Another interesting finding of these studies was the observation that steady-state tissue retinoid levels 
were unchanged. Despite increased uptake in some tissues, there was no quantitative change in tissue 
retinoid levels. This could suggest that the increase in retinoid uptake was not matched by an increase 
in the capability to store retinoid within the cell, and the excess retinoid taken up was redistributed 
throughout the body. This indicates that the retinoid-storage capacity of a tissue, given normal dietary 
retinoid intake levels, resides within the tissue. In addition to skeletal muscle, heart, and adipose tissue, 
LpL has also been shown to be an important mediator of chylomicron retinoid uptake in mouse and rat 
mammary tissue [51,52]. 
It is evident that extrahepatic tissues can take up postprandial retinyl ester from chylomicrons and 
that in RBP-deficiency this is sufficient to maintain  normal retinoid homeostasis provided dietary 
retinoid is sufficient. The mechanisms which mediate retinyl ester uptake in the periphery are only 
starting to be elucidated. 
5.3. Retinoid Homeostasis in Extrahepatic Tissues 
This section will consider retinoid homeostasis and function in several specific tissues. Special 
attention  will  be  given  to  white  adipose  tissue,  with  emphasis  on  the  recent  finding  that 
adipose-derived RBP may be an important signaling molecule in metabolic disease [143]. Similarly, 
the importance of retinoid homeostasis will be discussed in the heart, where recent studies have linked 
retinoid  signaling  and  heart  dysfunction  [130],  and  the  eye,  where  retinoid  metabolism  retains 
considerable research interest [144,145]. 
5.3.1. White Adipose Tissue Retinoid Homeostasis  
White adipose tissue is a significant site of extra-hepatic retinoid storage, accounting for ~15% of 
tissue retinoid stores in the adult rat [146]. Adipocytes and the stromal-vascular fraction of adipose 
have been shown to express key mediators of retinoid metabolism, supporting the notion that retinoid 
signaling is an important mediator of adipose physiology [147]. Within adult adipose tissue, RBP is 
predominantly expressed in adipocytes, with only weak expression in stromal-vascular cells [146]. 
Conversely, CRBPI was found to have relatively higher expression in the stromal-vascular cells versus 
adipocytes, though in vitro experiments show that retinoic acid can upregulate CRBPI expression in 
adipocytes [146,148]. CRBPIII has been shown to be expressed in adipose tissue homogenates [149] 
and  in  differentiated  3T3-L1  adipocytes  in  vitro  [150].  However,  through  the  use  of  a  specific  
CrbpIII-LacZ mouse, expression of this gene appears to be restricted to the vascular endothelial cells 
of adipose tissue [151]. The mRNA transcripts for retinoic acid receptor-α, -β, and -γ have all been 
reported  to  be  expressed  in  adipose  tissue  [152,153].  However,  work  in  differentiated  3T3-L1 
adipocytes reveals only a low level of RAR-α at the protein level [154]. Similarly, mRNA for the three 
major  retinoid  X  receptor  isoforms  is  also  expressed  in  adipose/3T3-L1  adipocytes  [153].  The 
synthesis of retinyl ester in adipose tissue was presumed to be mediated by LRAT, but this is certainly 
not the case, since LRAT-deficient mice have increased levels of adipose retinyl ester stores. Given the 
importance of LRAT in the synthesis of retinyl ester in the liver and nearly all other tissues, adipose Nutrients 2011, 3  
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levels of retinyl ester would be expected to be lower than WT levels, yet a greater than 3-fold increase 
in retinyl ester was observed [39,40,91]. This observation suggests that there is an unidentified enzyme 
expressed within adipocytes, the cellular site of retinoid storage within adipose tissue [146], which can 
synthesize retinyl ester. 
There  are  several  studies  that  indicate  an  important  role  for  retinoid  signaling  in  adipose 
tissue physiology,  including  the  observation  that  retinoic  acid  can  inhibit  adipogenesis  [147,155],  
CRBPI-deficient mice show increased adiposity [156], and CRBPIII-deficient mice have altered lipid 
metabolism and decreased adiposity [150]. Although CRBPIII was originally identified as a cellular 
retinol-binding  proteins  based  on  the  ability  of  the  recombinant  protein  to  bind  retinol,  a  true 
physiological  ligand  for  CRBPIII  has  not  been  identified.  It  seems  possible,  even  likely,  that  the 
actions of CRBPIII in lipid metabolism may involve other ligands than retinol. 
5.3.2. Adipose-Derived RBP and Metabolic Disease  
In addition to research studying the importance of retinoid signaling on adipose tissue biology, a 
novel role for adipocyte-derived RBP in metabolic disease has been proposed. As discussed above, the 
sole established physiologic role for RBP is to mobilize hepatic retinoid stores and transport retinol in 
the  circulation  [47].  Moreover,  RBP-deficient  mice  and  RBP-deficient  humans  have  a  similar 
relatively mild phenotype. However, work from Kahn and colleagues shows that RBP-deficient mice 
display  enhanced  insulin  sensitivity  [143].  This  observation,  coupled  with  data  from  a  number  
of  follow-up  studies,  suggests  that  adipose-derived  RBP  may  be  a  significant  contributor  to 
metabolic disease. 
In 2005, Kahn and colleagues published a convincing series of studies leading to the conclusion that 
RBP  is  an  important  mediator  of  insulin  resistance  in  obesity  and  type  2  diabetes  [143].  It  was 
previously known that mice with an adipose-specific deletion of the glucose transporter, GLUT4, were 
insulin resistant [157]. Yang et al. demonstrated that these mice over-express RBP in adipose tissue 
and  that  circulating  levels  of  RBP  were  elevated  in  adipose-specific  GLUT4-deficient  mice.  RBP 
expression in the liver was unchanged, suggesting that the increase in serum RBP was adipose-derived. 
Treatment  of  adipose-GLUT4-deficient  mice  with  the  PPAR-gamma  agonist,  rosiglitazone,  was 
associated with improved insulin sensitivity and glucose tolerance. This improvement was paralleled 
by a normalization of circulating RBP levels. Interestingly, increased circulating RBP levels were 
found to be a common feature of multiple mouse models of insulin resistance, and serum RBP levels 
were also increased in human subjects with diabetes. Further evidence suggesting a role for RBP in 
modulating insulin sensitivity came from experimental manipulations of circulating RBP levels. Mice 
over-expressing human RBP in skeletal muscle have increased serum RBP levels and were found to be 
insulin resistant, an observation mirrored by chronic treatment with purified RBP protein. Conversely, 
RBP-deficient mice have enhanced insulin sensitivity, as do mice with lowered circulating RBP levels 
following fenretinide treatment. Taken together these studies clearly indicate that increased circulating 
RBP is associated with insulin resistance, whereas lowered serum RBP is associated with enhanced 
insulin sensitivity. The publication of these studies led to the suggestion that RBP is a novel adipokine 
and a potential therapeutic target in human type II diabetes [158–160]. Nutrients 2011, 3  
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Follow-up studies into the correlation between serum RBP levels and altered insulin sensitivity in 
humans have not resulted in consensus on this point. Several studies have confirmed the observation 
linking insulin resistance to high circulating levels of RBP. Indeed this concept has been expanded to 
suggest that the ratio of retinol to RBP more strongly correlates with insulin sensitivity [161–166]. 
However, other groups have been unable to show an association between high serum RBP levels and 
insulin resistance [167–172]. It is apparent that further study is required to definitively establish a link 
between elevated serum RBP levels and insulin resistance in humans.  
The studies mentioned above suggest that RBP is an important contributor to metabolic disease. 
What  remains  unclear  is  whether  this  effect  is  mediated  through  retinoid  signaling  or  a  hitherto 
unknown mechanism of RBP action. Studies into the molecular mechanisms of RBP-induced insulin 
resistance have been recently reviewed elsewhere [173,174]. There are a growing number of studies 
that indicate an intersection between energy balance, metabolic disease, and retinoid signaling. These 
developments have opened up an exciting area of retinoid biology and brought renewed attention to 
this essential nutrient. 
5.3.3. Retinoid Homeostasis in the Heart  
Another expanding and important area of retinoid biology is the importance of retinoid signaling in 
the heart. While it has been well established that retinoic acid is an important signaling molecule 
during  heart  development  in  the  embryo,  there  is  a  growing  body  of  evidence  that  suggests  this 
molecule is also an important factor in heart disease and cardiac remodeling [130]. In several animal 
models  of  heart  disease,  retinoic  acid  supplementation  has  been  shown  to  have  beneficial  effects  
on tissue  pathology. Experiments employing  rat  cardiomyocytes  in  vitro have shown that  retinoic  
acid  can  attenuate  cardiomyocyte  hypertrophy  induced  by  endothelin-1,  phenylephrine,  and 
angiotensin-II  [175–178].  Following  the  promising  results  of  these  in  vitro  studies,  experiments  
in whole animals have borne out the hypothesis that retinoic acid may suppress cardiac hypertrophy 
in vivo. Retinoic acid treatment has proven effective in attenuating cardiac remodeling in a rat pressure 
overload model (by aortic banding) and a rat model of myocardial infarction [179,180]. Experimental 
myocardial  infarction  is  also  associated  with  an  increase  in  heart  retinoid  metabolism,  with  a 
significant mobilization of retinoid from the liver to the heart observed in infarcted versus control 
animals [181]. In contrast to the beneficial effects of retinoic acid in a disease setting, there is evidence 
to  suggest  that  retinoid-deficiency  may  have  adverse  effects  on  the  heart.  Retinoid-deficiency  in 
female rats has been associated with markers of cardiac remodeling and ventricular dysfunction [182]. 
How these animal studies relate to heart disease in humans remains largely untested. Unfortunately, in 
the context of acute promyelocytic leukemia, retinoic acid treatment has been associated with cardiac 
dysfunction in at least one case report [183]. Continuing research aimed at verifying the therapeutic 
potential of retinoic acid treatment in heart disease is warranted. 
5.3.4. Retinoid Homeostasis in the Eye  
There has been a very substantial body of research carried out in the last decade aimed at defining 
better retinoid metabolism and actions within the eye. Notably, this literature has established many 
linkages between genetic eye disease and genes involved in retinoid metabolism and transport. This Nutrients 2011, 3  
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had long been anticipated but has only been established through groundbreaking research carried out in 
the last 10 to 15 years. In this review, we will only focus on a few key advances for understanding 
retinoid metabolism in the eye, and we will not focus on relationships of these processes with disease. 
A number of extensive and authoritative reviews on this topic have been published recently [145,146] 
and consequently the reader is referred to these reviews for more detail. 
The central question regarding retinoid metabolism in vision that was left unanswered from the 
early work of Wald and others [184,185] concerned the mechanism through which all-trans-retinoid is 
converted to the energetically less stable 11-cis-retinoid that is required for vision. Based on work 
commencing  in  the  mid-1980s,  Rando  and  colleagues  and  others  proposed  the  existence  of  an 
isomerohydrolase that converts all-trans-retinyl ester to 11-cis-retinol [186–188]. It was proposed that 
the  isomerohydrolase  utilizes  energy  liberated  from  the  hydrolysis  of  the  ester  bond  to  drive 
steroisomerization  from  the  all-trans-  to  the  energetically  less  favorable  11-cis-configuration. 
Recently, it has been demonstrated that the abundant retinal pigment epithelium protein (RPE) RPE65 
is the isomerohydrolase [189–191]. RPE65-deficient mice have high levels of all-trans-retinyl esters in 
their eyes and no detectable 11-cis-retinoids [192]. These mice are blind because they are unable to 
generate 11-cis-retinoid needed for vision. As mentioned above in Section 2.2, RPE65 structurally 
resembles BCMO1 and BCMO2 and, like these two other enzymes, contains a conserved Fe
2+ binding 
site  that  is  required  for  catalytic  activity  [18].  RPE65  (originally  referred  to  as  p63)  had  
been  identified  in  the earlier  literature as  a  cell  surface receptor for RBP, but  this  has  proven to  
be incorrect [6,192]. 
Another  important  advance  in  understanding  retinoid  metabolism  in  the  eye  has  been  the 
elucidation  of  the  mechanism  through  which  all-trans-retinoid  produced  upon  photoexcitation  is 
removed from the photoreceptor outer segments for transport back to the RPE and reconversion to  
11-cis-retinoid.  This  process  has  been  identified  to  require  a  retina-specific  ATP  binding  cassette 
transporter referred to as either ABCR or ABCA4, which localizes to the disc membranes present in 
rod and cone outer seqments [193–195]. ABCR-deficient mice show a much slower rate of removal of 
all-trans-retinal  from  the  retina  following  exposure  to  light  [196,197].  This  is  accompanied  by  
an increase in retinal-phosphotidylethanolamine adducts, which have been identified as the substrates 
for  ABCR-catalyzed  removal  of  all-trans-retinal  from  the  disc  membranes  to  the  cytoplasmic  
space [198,199]. 
Another  important  advancement  in  understanding  retinoid  metabolism  in  the  eye  has  been  the 
identification of retinol dehydrogenase 8 (RDH8; also referred to as photoreceptor RDH or prRDH) as 
one enzyme within the outer segments of the retina that catalyzes the reduction of all-trans-retinal to 
all-trans-retinol [200–202]. RDH8-deficient mice show a slower rate, by several orders of magnitude,  
of clearance for all-trans-retinal  from the retina  following  exposure  of dark adapted  animals  to  a  
flash of light [200–203]. However, the kinetics of rhodopsin regeneration for RDH8-deficient mice is 
not  different  than  that  of  WT  mice,  suggesting  that  other  dehydrogenases  are  also  involved  in  
all-trans-retinal  reduction  to  all-trans-retinol  within  the  photoreceptors.  Subsequent  studies  by 
Palczewski  and  colleagues  identified  RDH12  as  another  photoreceptor  dehydrogenase  that  is 
contributes to all-trans-retinal reduction, although RDH12 too was observed to be dispensible [203]. Nutrients 2011, 3  
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In summary, the last decade has been a very exciting one for the study of retinoid metabolism in the 
eye. Much has been learned and the eye remains the organ where retinoid metabolism is best and most 
deeply understood.  
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